Social Media Ideas for Fate Therapeutics

Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein

Tolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas a...

Argenx Expands Immunology Portfolio with $2.2B Buyout of Forte Biosciences

Earlier this month Forte announced positive results for its lead candidate FB102, from a Phase Ib trial assessing the anti-CD122 monoclonal antibody in vitiligo. FB102 achieved a 2...

FDA extends review of Capricor cell therapy; Pain drug startup to go public

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the pub...

PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry market

PTC Therapeutics has struck a deal to buy Sangamo Therapeutics’ Fabry disease program for $111 million upfront, outbidding Astellas and TerSera Therapeutics for the near-approval g...

Cellogen Therapeutics is developing CAR-T cell therapies for blood cancers in India

The Delhi company designs and manufactures its own cell and gene therapies and is preparing a first clinical trial with Christian Medical College, Vellore.

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.

With $263M, LifeMine unearths a new drug for organ transplants

Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplante...

Immuneel, Tata Memorial Centre partner to advance cell and gene therapy research

Among the first projects identified under the partnership is a Phase 2 extension study evaluating the safety and efficacy of IMN-003A cell therapy in adult and paediatric patients...

Arpeggio plays final chord as biotech disbands on poor prospects for Nrf2 program

Arpeggio Biosciences’ eight-year song has come to an end, as the transcriptome biotech’s CEO admitted the that company’s Nrf2 program had begun to “unravel.”

PTC takes a chance on Sangamo’s Fabry disease gene therapy

Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach

TScan axes 75% of workforce to make room for solid tumor programs

TCR-T specialist TScan Therapeutics will reduce its workforce by 75% following the pause of its hematological and autoimmune programs.

PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy

Sangamo Therapeutics filed for Chapter 11 bankruptcy in June after its search for strategic alternatives failed to find a path forward for the company. PTC Therapeutics’ auction wi...

Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday

Actimed Therapeutics has brought the full rights to its wasting disease drug back in-house, securing “strategic control” over the asset but losing out on a shot at over $120 millio...

<![CDATA[Steer Bio Targets Lymphedema with Regenerative Cell Therapy Platform]]>

Novel Epigenetic Therapy Targets Treatment-Resistant and TP53-Mutant AML

The results of a preclinical study across multiple models of acute myeloid leukemia found that the investigational hypomethylating agent, NTX-301 remained effective in treatment-re...

Skye and Redx form new entity with $125M to advance fibrosis assets

Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new publ...

Six TIL therapy companies to watch out for 

The only TIL therapy approved so far is Amtagvi for melanoma. Here are six companies with promising TIL therapies in the clinic. The post Six TIL therapy companies to watch out for...

Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellera

AbCellera’s T-cell engager platform has reeled in a second client this summer, with Vertex paying $28 million upfront for a collaboration that will include autoimmune conditions.

AbCellera, Vertex partner on next-gen T-cell engagers

The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medi...

Natera teams with Angiex on cancer drug trial monitoring

Natera inked a collaboration deal with biotech Angiex to assess the use of its Signatera blood test, which looks for small traces of cancer DNA in patients who have been diagnosed...

UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies

Three deaths have forced Novartis to pause development of its CD19 CAR-T candidate in autoimmune diseases, just as Bristol Myers Squibb has halted a similar program due to immune-r...

Repligen: Acquisition To Add Cell Therapy Capabilities

Why Axiom hopes it’s ‘solved 2 major potholes’ that have hurt other stem cell biotechs

When Axiom's stem cell therapy demonstrated a 0% mortality rate over two years in potentially fatal newborn neurological diseases this week, the biotech's leadership saw a broader...